Sandu Pharmaceuticals Managing Director Umesh Sandu passes away

0 min read Updated on 19 Jun 2026, 04:35 PM

Reviewed by

Suketu GScanX News Team

AI Summary

Sandu Pharmaceuticals Limited announced the demise of its Managing Director and Promoter, Shri Umesh Sandu, on June 19, 2026. The company noted his passing as an irreparable loss and stated that he ceased to be a member of the Audit Committee and Stakeholders Relationship Committee. The disclosure was made to the stock exchange in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

*this image is generated using AI for illustrative purposes only.

Sandu Pharmaceuticals Limited announced the demise of its Managing Director and Promoter, Shri Umesh Sandu, on June 19, 2026. The company described his passing as an irreparable loss, noting that it had immensely benefitted from his vision and active participation in various committee and board meetings during his tenure. Consequently, he ceases to be a member of the Audit Committee and Stakeholders Relationship Committee.

The Chairman, all Directors, and employees of the company conveyed deep sympathy and condolences to his family members. The intimation was submitted to the stock exchange in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Details of the Director

The company provided specific details regarding the director's status and shareholding at the time of his demise.

Sr. No.	Name of the Director	Capacity	Date of demise	Promoter/ Promoter group	No of Shares Held
1.	Shri Umesh Sandu (DIN:01132141)	Managing Director	19.06.2026	Promoter	13,88,693

Historical Stock Returns for Sandu Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.54%	-2.60%	+7.64%	+8.64%	-16.16%	-11.06%

Who will be appointed as the successor to manage the company's operations following the Managing Director's demise?

How will the company address the potential leadership vacuum in the Audit Committee and Stakeholders Relationship Committee?

What impact will the death of a key promoter have on the company's strategic direction and future growth plans?

Read Next Article

Sandu Pharmaceuticals Receives GST Detention Order, Pays ₹31,699 Penalty; Proceedings Dropped

1 min read Updated on 07 May 2026, 06:23 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

AI Summary

Sandu Pharmaceuticals received a GST detention order from the Office of Assistant Commissioner, Jurisdiction Sector 3 (Mobile Squad-1) Shamli, Uttar Pradesh, on 07/05/2026, citing a discrepancy between invoice quantity and physically verified quantity of goods. The company accepted the liability and paid a penalty of ₹31,699 on 06/05/2026. The GST authority subsequently dropped the proceedings, and the company has confirmed there is no major impact on its financial or operational activities.

*this image is generated using AI for illustrative purposes only.

Sandu Pharmaceuticals has disclosed the receipt of a detention order from the Office of Assistant Commissioner, Jurisdiction Sector 3 (Mobile Squad-1) Shamli, Uttar Pradesh, under the provisions of Regulation 30 read with sub-para 20 of Para A of Part A of Schedule III of the Listing Regulations. The order, received on 07/05/2026, pertains to a discrepancy between the quantity of goods as per invoice and the quantity established during physical verification of the goods.

GST Detention Order: Key Details

The detention order was issued under Section 129(1) of the State Goods and Services Tax Act, 2017/Union Territory Goods and Services Tax Act, 2017 and the Central Goods and Services Tax Act, 2017, as well as under Section 20 of the Integrated Goods and Services Tax Act, 2017. The following table summarises the key details of the regulatory action:

Parameter:	Details
Issuing Authority:	Office of Assistant Commissioner, Jurisdiction Sector 3 (Mobile Squad-1) Shamli, Uttar Pradesh
Nature of Order:	Order of Detention under Section 129(1) of SGST/UTGST Act, 2017 & CGST Act, 2017; Section 20 of IGST Act, 2017
Date of Receipt:	07/05/2026
Reason:	Discrepancy in quantity as per invoice vs. quantity as per physical verification of goods
Penalty Paid:	₹31,699
Date of Penalty Payment:	06/05/2026
Status of Proceedings:	Dropped by GST authority

Company Response and Financial Impact

Based on its own assessment, Sandu Pharmaceuticals accepted the liability and paid the penalty amounting to ₹31,699 on 06/05/2026. Following the payment, the GST authority dropped the proceedings against the company. The company has stated that there is no major impact on its financial, operational, or other activities as a result of this order.

The disclosure was made by Pratika Mhambray, Company Secretary and Compliance Officer, on behalf of Sandu Pharmaceuticals, and communicated to BSE Limited on 07/05/2026.

Historical Stock Returns for Sandu Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.54%	-2.60%	+7.64%	+8.64%	-16.16%	-11.06%

Could this GST detention incident trigger increased scrutiny from tax authorities on Sandu Pharmaceuticals' future shipments, potentially disrupting its supply chain operations?

What systemic changes might Sandu Pharmaceuticals implement in its invoicing and inventory management processes to prevent similar quantity discrepancies in the future?

How might repeated GST compliance issues, even minor ones, affect Sandu Pharmaceuticals' GST compliance rating and its ability to claim input tax credits going forward?